Nitric oxide - Novan Inc

Drug Profile

Nitric oxide - Novan Inc

Alternative Names: NVN-1000 SB-206; SB-206

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novan Inc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Genital warts; Human papillomavirus infections; Molluscum contagiosum
  • Discontinued Staphylococcal infections

Most Recent Events

  • 25 Jan 2018 Phase-II clinical trials in Molluscum contagiosum (In children, In adolescents) (Topical)
  • 20 Mar 2017 Novan completes a phase II trial in Genital warts in USA (NCT02462187; 9213297)
  • 29 Nov 2016 Novan plans pivotal phase III trial for Genital warts in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top